Article
Medicine, General & Internal
Nuria Carreras-Dieguez, Ariel Glickman, Meritxell Munmany, Georgina Casanovas, Nuria Agusti, Berta Diaz-Feijoo, Adela Saco, Beatriz Sanchez, Lydia Gaba, Martina Aida Angeles, Jaume Pahisa, Esther Fernandez-Galan, Aureli Torne, Pere Fuste
Summary: ROMA and CPH-I perform better than tumor markers alone in identifying patients with EOC or MCO. They can be helpful in assessing the risk of malignancy in adnexal masses, especially in cases where ultrasonographic diagnosis is challenging (stage I EOC, inconclusive diagnosis of malignancy by ultrasound features).
Article
Oncology
Haixia Wang, Pingping Liu, Hai Xu, Hongmei Dai
Summary: The combined detection of HE4, CA125, and ROMA is more effective than diagnosis with any single indicator, with high application value in the early diagnosis of ovarian cancer.
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
(2021)
Article
Reproductive Biology
Yan Rong, Li Li
Summary: The study evaluated the clinical value of early clearance of HE4 and CA125 in predicting platinum sensitivity and prognosis in patients with ovarian cancer. The results showed that early clearance of HE4 and CA125 could predict platinum response and prognosis, aiding in predicting the risk of progression and relapse.
JOURNAL OF OVARIAN RESEARCH
(2021)
Article
Reproductive Biology
Jorge A. Alegria-Banos, Jose C. Jimenez-Lopez, Arely Vergara-Castaneda, David F. Cantu de Leon, Alejandro Mohar-Betancourt, Delia Perez-Montiel, Gisela Sanchez-Dominguez, Mariana Garcia-Villarejo, Cesar Olivares-Perez, Angel Hernandez-Constantino, Acitlalin Gonzalez-Santiago, Miguel Clara-Altamirano, Liz Arela-Quispe, Diddier Prada-Ortega
Summary: A prospective-longitudinal study was conducted among women with advanced epithelial ovarian cancer (AEOC) who were treated with NACT, and it was found that serum HE4 levels were independently associated with therapeutic response, providing potential insights for predicting treatment outcomes.
JOURNAL OF OVARIAN RESEARCH
(2021)
Article
Obstetrics & Gynecology
Hui-Jing Luo, Zhi-Dong Hu, Ming Cui, Xiao-Fang Zhang, Wen-Yan Tian, Chao-Qun Ma, Ya-Nv Ren, Zuo-Liang Dong
Summary: This study evaluated the ability of CA125, HE4, ROMA, and CPH-I to differentiate primary ovarian cancer from borderline and benign ovarian tumors, and explored ideal cutoff values. The results showed that ROMA and CPH-I outperformed single tumor markers in identifying ovarian cancer, while the diagnostic performance of HE4 was significantly higher than that of CA125. For postmenopausal women, CA125 performed equivalently to ROMA and CPH-I.
JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH
(2023)
Article
Multidisciplinary Sciences
Syamel Muhammad, Reyhan Julio Azwan, Rauza Sukma Rita, Restu Susanti, Yusrawati
Summary: This study investigates the predictive role of IL6, CA-125, and HE4 in tumor resectability in pre-operative patients with advanced epithelial ovarian cancer and finds a correlation between these markers and tumor resectability.
Article
Medical Laboratory Technology
Cheng Zhu, Nenghua Zhang, Ailing Zhong, Kangjia Xiao, Renquan Lu, Lin Guo
Summary: This study found that TK1 is a potential biomarker in the detection of ovarian carcinoma, and the new diagnostic index ROMI has better diagnostic performance than ROMA in distinguishing malignant ovarian tumors from benign masses.
CLINICA CHIMICA ACTA
(2022)
Article
Oncology
Doan Tu Tran, Van Khoa Vo, Minh Tam Le, Linus Chuang, Vu Quoc Huy Nguyen
Summary: This study evaluated the diagnostic performances of CPH-I and ROMA in preoperative prediction of ovarian cancer. The results showed similar discriminatory performances and comparable sensitivities/specificities between the two indices. CPH-I could be a simple alternative to ROMA in clinical practice.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Arpita Suri, Vanamail Perumal, Prajwal Ammalli, Varsha Suryan, Sanjiv Kumar Bansal
Summary: The study compared the diagnostic accuracy of ROMA, HE-4, and CA125 in early diagnosis and screening of epithelial ovarian cancer. ROMA was found to be the best marker for differentiating EOC from benign ovarian masses in postmenopausal women, while HE4 showed promise as a diagnostic predictor in premenopausal women. Further research is needed to explore the full potential of HE4 in premenopausal women.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Chloe E. Barr, Kelechi Njoku, Gemma L. Owens, Emma J. Crosbie
Summary: This study evaluated the value of two simple, non-invasive urine biomarkers, CA125 and HE4, for the diagnosis of ovarian cancer in symptomatic women. The results showed that urine levels of CA125 and HE4 were significantly higher in women with ovarian cancer compared to controls. A combination of urine CA125 and HE4 had a similar sensitivity to serum CA125 in detecting ovarian cancer, suggesting their potential as non-invasive diagnostic tools.
Article
Reproductive Biology
Li-Ping Gong, Xiao-Ying Li, Ying-Nan Wu, Shuang Dong, Shuang Zhang, Ya-Nan Feng, Ya-Er Lv, Xi-Juan Guo, Yan-Qing Peng, Xiao-Shan Du, Jia-Wei Tian, Cong-Xin Sun, Li-Tao Sun
Summary: This study aimed to develop and validate a nomogram based on the O-RADS for predicting the malignancy risk of adnexal masses with complex ultrasound morphology. Independent risk factors for malignant tumors were determined and incorporated into the nomogram model. The nomogram showed good discrimination and calibration in both the training and validation cohorts, and had higher AUC and net benefit than the O-RADS.
JOURNAL OF OVARIAN RESEARCH
(2023)
Article
Biochemical Research Methods
Robinson Karunanithy, Suthakaran Ratnasingam, Torrey Holland, Poopalasingam Sivakumar
Summary: Detection of cancer before the appearance of symptoms is crucial for successful treatment. This study developed a user-friendly method using laser-induced breakdown spectroscopy to detect the HE4 biomarker, which is challenging to detect early due to the lack of symptoms. The method improved the sensitivity and selectivity of biomarker detection through cross-linking elemental particles and simultaneous detection of Fe and Si.
BIOCONJUGATE CHEMISTRY
(2023)
Article
Medicine, Research & Experimental
Mariona Rius, Pere Fuste, Cristina Ros, Angeles Martinez-Zamora, Cristian deGuirior, Meritxell Gracia, Eduard Mension, Francisco Carmona
Summary: This study found that HE4 is a more useful tumor biomarker for diagnosing ovarian carcinoma in patients with ovarian endometriosis when ultrasound results are inconclusive, compared to CA125.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
(2021)
Article
Multidisciplinary Sciences
Shiyun Li, Jiaqi Liu, Yuanhuan Xiong, Peipei Pang, Pinggui Lei, Huachun Zou, Mei Zhang, Bing Fan, Puying Luo
Summary: This study developed a two-dimensional radiomics approach using computed tomography to differentiate between benign and malignant ovarian neoplasms. By extracting texture features, selecting the best features, and building a radiomics model, the method improved the classification and diagnosis of ovarian tumors effectively.
SCIENTIFIC REPORTS
(2021)
Article
Biochemical Research Methods
Melike Bilgi Kamac, Muhammed Altun, Merve Yilmaz, Mustafa Kemal Sezginturk
Summary: In this study, a novel disposable dual immunosensor based on dual screen-printed carbon electrodes modified with reduced graphene oxide, polythionine, and gold nanoparticles was developed for label-free simultaneous determination of CA125 and HE4 in ovarian cancer diagnosis and monitoring. The immunosensors exhibited high selectivity, sensitivity, and repeatability, with high correlation coefficients for two linear ranges. They also demonstrated high application and storage stability, as well as reusability. These disposable dual immunosensors can be used in point-of-care tests for rapid and practical simultaneous determination of CA125 and HE4 with high performance.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY
(2023)